JP2010522208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522208A5 JP2010522208A5 JP2009554753A JP2009554753A JP2010522208A5 JP 2010522208 A5 JP2010522208 A5 JP 2010522208A5 JP 2009554753 A JP2009554753 A JP 2009554753A JP 2009554753 A JP2009554753 A JP 2009554753A JP 2010522208 A5 JP2010522208 A5 JP 2010522208A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- liquid formulation
- imc
- polysorbate
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012669 liquid formulation Substances 0.000 claims 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 239000004471 Glycine Substances 0.000 claims 3
- 229950006647 cixutumumab Drugs 0.000 claims 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 229940068968 polysorbate 80 Drugs 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000007979 citrate buffer Substances 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91974407P | 2007-03-22 | 2007-03-22 | |
| PCT/US2008/057718 WO2008116103A2 (en) | 2007-03-22 | 2008-03-20 | Stable antibody formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010522208A JP2010522208A (ja) | 2010-07-01 |
| JP2010522208A5 true JP2010522208A5 (cg-RX-API-DMAC7.html) | 2011-04-28 |
Family
ID=39766776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554753A Pending JP2010522208A (ja) | 2007-03-22 | 2008-03-20 | 安定な抗体処方物 |
Country Status (18)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| TW200838559A (en) * | 2006-11-29 | 2008-10-01 | Imclone Systems Inc | Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| CN118324847A (zh) | 2008-10-29 | 2024-07-12 | 阿布林克斯公司 | 单域抗原结合性分子的纯化方法 |
| US9393304B2 (en) | 2008-10-29 | 2016-07-19 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
| JP5933975B2 (ja) * | 2008-11-12 | 2016-06-15 | メディミューン，エルエルシー | 抗体製剤 |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| PT2376116E (pt) | 2008-12-12 | 2016-02-24 | Boehringer Ingelheim Int | Anticorpos anti-igf |
| TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
| WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
| MX351706B (es) | 2010-09-17 | 2017-10-25 | Baxalta Inc | Estabilizacion de inmunoglobulinas a traves de una formulacion acuosa con histidina a ph acido debil a neutro. |
| CN104800844A (zh) | 2010-11-05 | 2015-07-29 | 诺华有限公司 | 使用il-17拮抗剂治疗类风湿性关节炎的方法 |
| CN103501825B (zh) | 2011-05-02 | 2017-03-15 | 免疫医疗公司 | 用于小体积施用的同种异型选择的抗体的超滤浓缩 |
| CN104136047B (zh) * | 2011-10-26 | 2018-02-06 | 安姆根有限公司 | 减少或消除由暴露于uv光而引起的蛋白质修饰和降解的方法 |
| PT3378535T (pt) | 2011-10-28 | 2023-02-06 | Prothena Biosciences Ltd | Anticorpos humanizados que reconhecem a alfa-sinucleína |
| WO2013112945A1 (en) | 2012-01-27 | 2013-08-01 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| AR091902A1 (es) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
| AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| AR094821A1 (es) * | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| NZ707168A (en) | 2012-12-26 | 2016-09-30 | Wockhardt Ltd | Pharmaceutical composition of insulins |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| NL1040254C2 (en) * | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| EP3129051A1 (en) | 2014-04-08 | 2017-02-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| IL307913A (en) | 2014-12-04 | 2023-12-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of acute myeloid leukemia |
| EA035719B1 (ru) * | 2015-02-09 | 2020-07-30 | Юсб Биофарма Спрл | Фармацевтический состав |
| CN108136218B (zh) | 2015-05-20 | 2022-12-13 | 詹森生物科技公司 | 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体 |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| HUE053366T2 (hu) | 2015-11-03 | 2021-06-28 | Janssen Biotech Inc | Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk |
| JP6992262B2 (ja) * | 2016-03-31 | 2022-02-15 | 東ソー株式会社 | 変性抗体測定試薬の製造方法 |
| WO2018187074A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | 詹森生物科技公司 | 治疗高危多发性骨髓瘤的方法 |
| MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
| CN112206320B (zh) * | 2019-07-12 | 2025-02-25 | 鲁南制药集团股份有限公司 | 一种cd47单克隆抗体冻干粉制剂及其制备工艺 |
| CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| CA2103059C (en) * | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| ATE442862T2 (de) * | 2000-10-12 | 2009-10-15 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| NO345566B1 (no) * | 2001-06-26 | 2021-04-19 | Amgen Inc | OPGL bindende antistoff, farmasøytisk sammensetning samt anvendelse derav |
| DE60235013D1 (de) * | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| EP1475101B1 (en) * | 2002-02-14 | 2010-10-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing solution pharmaceuticals |
| KR20050109489A (ko) * | 2003-02-13 | 2005-11-21 | 화이자 프로덕츠 인크. | 항-인슐린양 성장인자 ｉ 수용체 항체의 용도 |
| US7638605B2 (en) * | 2003-05-01 | 2009-12-29 | ImClone, LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| AR046071A1 (es) * | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| MXPA06001634A (es) * | 2003-08-13 | 2006-04-28 | Pfizer Prod Inc | Anticuerpos humanos modificados igf-1r. |
| AU2006247039B2 (en) * | 2005-05-19 | 2011-03-03 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| NZ564098A (en) * | 2005-06-15 | 2010-04-30 | Schering Corp | Anti-IGF1R antibody formulations |
| BRPI0709229A2 (pt) * | 2006-03-28 | 2011-06-28 | Hoffmann La Roche | formulação de anticorpo monoclonal humano anti-igf-ir |
-
2008
- 2008-03-20 EP EP08744136A patent/EP2136839A4/en not_active Withdrawn
- 2008-03-20 CA CA002681743A patent/CA2681743A1/en not_active Abandoned
- 2008-03-20 WO PCT/US2008/057718 patent/WO2008116103A2/en not_active Ceased
- 2008-03-20 CN CN200880009446A patent/CN101668540A/zh active Pending
- 2008-03-20 MX MX2009010179A patent/MX2009010179A/es not_active Application Discontinuation
- 2008-03-20 US US12/528,882 patent/US20100260766A1/en not_active Abandoned
- 2008-03-20 JP JP2009554753A patent/JP2010522208A/ja active Pending
- 2008-03-20 UA UAA200909552A patent/UA96473C2/ru unknown
- 2008-03-20 KR KR1020097019642A patent/KR20090113340A/ko not_active Abandoned
- 2008-03-20 EA EA200970880A patent/EA200970880A1/ru unknown
- 2008-03-20 AU AU2008228823A patent/AU2008228823A1/en not_active Abandoned
- 2008-03-20 BR BRPI0809112-9A patent/BRPI0809112A2/pt not_active IP Right Cessation
-
2009
- 2009-08-10 IL IL200321A patent/IL200321A0/en unknown
- 2009-08-13 ZA ZA200905636A patent/ZA200905636B/xx unknown
- 2009-08-28 CR CR11005A patent/CR11005A/es not_active Application Discontinuation
- 2009-09-18 DO DO2009000222A patent/DOP2009000222A/es unknown
- 2009-09-18 TN TNP2009000382A patent/TN2009000382A1/fr unknown
- 2009-09-21 EC EC2009009642A patent/ECSP099642A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010522208A5 (cg-RX-API-DMAC7.html) | ||
| JP2010529999A5 (cg-RX-API-DMAC7.html) | ||
| JP2011088913A5 (cg-RX-API-DMAC7.html) | ||
| AR124140A2 (es) | Formulaciones de anticuerpos | |
| NZ595526A (en) | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant | |
| UA96473C2 (ru) | Жидкая стойкая композиция, которая содержит антитело imc-а12 | |
| JP2006517944A5 (cg-RX-API-DMAC7.html) | ||
| UA107557C2 (xx) | Композиція антитіла офатумумабу | |
| JP2013527189A5 (cg-RX-API-DMAC7.html) | ||
| JP2007522094A5 (cg-RX-API-DMAC7.html) | ||
| WO2009048148A1 (ja) | シトルリンおよびアルギニンを含有する即効性血中アルギニン濃度上昇型経口剤 | |
| FI4374878T3 (fi) | Karbetosiinia käsittävä farmaseuttinen koostumus | |
| HRP20161577T1 (hr) | Inhibitori replikacije virusa gripe | |
| JP2014520852A5 (cg-RX-API-DMAC7.html) | ||
| JP2008531742A5 (cg-RX-API-DMAC7.html) | ||
| JP2005527551A5 (cg-RX-API-DMAC7.html) | ||
| CY1112917T1 (el) | Υγρες στοματικες συνθεσεις | |
| PE20130374A1 (es) | Composicion farmaceutica que comprende ibuprofeno | |
| JP2011111444A5 (cg-RX-API-DMAC7.html) | ||
| JP2011068692A5 (cg-RX-API-DMAC7.html) | ||
| EP1976554A4 (en) | DE-N-ACETYL-SIALIC ACID ANTIGENES, ANTIBODIES, AND METHOD FOR USE IN CANCER THERAPY | |
| RU2010104395A (ru) | Пероральные фармацевтические растворы, содержащие телбивудин | |
| JP2006342148A5 (cg-RX-API-DMAC7.html) | ||
| JP2006516279A5 (cg-RX-API-DMAC7.html) | ||
| NO20064085L (no) | Diettsupplement med stokiometrisk spesifikt kaliummagnesiumcitrate |